XBP vs INVA

For growth investors, XBP Global Holdings, Inc.

(XBP) is the stronger pick with 454. 1% revenue growth year-over-year, versus 18. 5% for Innoviva, Inc. (INVA). XBP Global Holdings, Inc. (XBP) offers the better valuation at 0. 0x trailing P/E, making it the more compelling value choice. Analysts rate Innoviva, Inc. (INVA) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, XBP Global Holdings, Inc.

(XBP) is the cheapest at 0. 0x versus Innoviva, Inc. at 6. 9x.

Over the past 5 years, Innoviva, Inc.

(INVA) delivered a total return of +77. 9%, compared to -75. 3% for XBP Global Holdings, Inc. (XBP). Over 10 years, the gap is even starker: INVA returned +108. 1% versus XBP's -74. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Innoviva, Inc.

(INVA) is the lower-risk stock at 0. 06β versus XBP Global Holdings, Inc. 's 1. 07β — meaning XBP is approximately 1772% more volatile than INVA relative to the S&P 500. On balance sheet safety, Innoviva, Inc. (INVA) carries a lower debt/equity ratio of 23% versus 5% for XBP Global Holdings, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), XBP Global Holdings, Inc.

(XBP) is pulling ahead at 454. 1% versus 18. 5% for Innoviva, Inc. (INVA). On earnings-per-share growth, the picture is similar: XBP Global Holdings, Inc. grew EPS 230. 0% year-over-year, compared to 816. 7% for Innoviva, Inc.. Over a 3-year CAGR, XBP leads at 63. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

XBP Global Holdings, Inc.

(XBP) is the more profitable company, earning 139. 5% net margin versus 63. 8% for Innoviva, Inc. — meaning it keeps 139. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: INVA leads at 38. 5% versus 1. 5% for XBP. At the gross margin level — before operating expenses — INVA leads at 72. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Innoviva, Inc.

(INVA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 06), +108. 1% 10Y return). Both have compounded well over 10 years (INVA: +108. 1%, XBP: -74. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (XBP (Technology) and INVA (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.